Javier Domingo
Research Subjects
Research Interests
Javier Domingo has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Juan Antonio Garcia Velasco
IVIRMA Global Research Alliance, IVIRMA Madrid, Spain
2 shared publications Ana Cobo
IVI-Valencia, Plaza de la Policía Local, 3 46025 Valencia, Spain
1 shared publication- Antonio Pellicer
Department of Paediatrics, Obstetrics and Gynecology, University of Valencia
1 shared publication Maria Martinez
IVI-Madrid, Rey Juan Carlos University, Av. del Talgo 68, 28023 Madrid, Spain
1 shared publicationSusana Rabadan
IVI-Madrid, Rey Juan Carlos University, Av. del Talgo 68, 28023 Madrid, Spain
1 shared publication
Latest Publications
- 1 December 2016
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 23 (6) , 465-469
Oocyte cryopreservation for fertility preservation in women with cancer
It is necessary to clarify the fertility preservation-related points of concern that often frighten patients or physicians when it comes to deciding about oocyte cryopreservation for fertility preservation, which are often perceived as procedure limitations, are sometimes real and often theoretical and may make the prognosis worse. Letrozole added to gonadotrophins for controlled ovarian stimulation is safe when applied to hormone-sensitive cancer patients as it avoids associated high estradiol levels. This benefit is only for estrogens, but not for progesterone. Triggering ovulation with gonadotropin releasing hormone agonist bolus and adding the gonadotropin releasing hormone antagonist after oocyte retrieval help minimize its effect. A random start is currently widespread as neither results nor offspring are compromised, and it avoids waiting for menstruation and, therefore, delaying treatment. The cumulative live birth rate is conditioned by the number of available oocytes and patient's age. Assisted reproductive technologies may help cancer patients to achieve pregnancy with good obstetric outcomes and apparent oncological safety. Although counseling should be provided on an individual basis, fertility preservation in cancer patients and later pregnancy in survivors after adequate treatment and follow-up should not be discouraged.
- 1 December 2016
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 23 (6) , 465-469
Oocyte cryopreservation for fertility preservation in women with cancer
It is necessary to clarify the fertility preservation-related points of concern that often frighten patients or physicians when it comes to deciding about oocyte cryopreservation for fertility preservation, which are often perceived as procedure limitations, are sometimes real and often theoretical and may make the prognosis worse. Letrozole added to gonadotrophins for controlled ovarian stimulation is safe when applied to hormone-sensitive cancer patients as it avoids associated high estradiol levels. This benefit is only for estrogens, but not for progesterone. Triggering ovulation with gonadotropin releasing hormone agonist bolus and adding the gonadotropin releasing hormone antagonist after oocyte retrieval help minimize its effect. A random start is currently widespread as neither results nor offspring are compromised, and it avoids waiting for menstruation and, therefore, delaying treatment. The cumulative live birth rate is conditioned by the number of available oocytes and patient's age. Assisted reproductive technologies may help cancer patients to achieve pregnancy with good obstetric outcomes and apparent oncological safety. Although counseling should be provided on an individual basis, fertility preservation in cancer patients and later pregnancy in survivors after adequate treatment and follow-up should not be discouraged.
- 1 December 2014
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 29 (6) , 722-728
Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer
- 1 December 2014
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 29 (6) , 722-728
Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer